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Tissue-specific heterogeneity of endothelial cells, both structural and functional, plays a crucial 
role in physiologic as well as pathologic processes, including inflammation, autoimmune diseases 
and tumor metastasis. This heterogeneity primarily results from the differential expression of ad-
hesion molecules that are involved in the interactions between endothelium and circulating im-
mune cells or disseminating tumor cells. Among these molecules present on endothelial cells is 
hyaluronan (HA), a glycosaminoglycan that contributes to primary (rolling) interactions through 
binding to its main receptor CD44 expressed on leukocytes and tumor cells. While the regulation 
of CD44 expression and function on either leukocytes or tumor cells has been well character-
ized, much less is known about the ability of endothelial cells to express HA on their surface. 
Therefore, in these studies we analyzed HA levels on tissue-specific endothelium. We used en-
dothelial cell lines of different origin, including lung, skin, gut and lymph nodes that had been 
established previously as model lines to study interactions between the endothelium and leuko-
cytes/tumor cells. Our results indicate that HA is accumulated on the surface of all endothelial 
cells examined. Moreover, retention of endogenous HA differs between the lines and may de-
pend on their tissue origin. Analysis of binding of exogenous HA reveals the presence of specific 
HA binding sites on all endothelial cell lines tested. However, the retention of endogenous HA 
and the binding of exogenous HA is mediated through a CD44-independent mechanism.
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INTRODUCTION
Hyaluronan (HA), a prevalent component of 
the extracellular and pericellular matrixes, is a non-
sulfated glycosaminoglycan (GAG) ubiquitously ex-
pressed by various cell types in almost all animal 
tissues (Laurent & Fraser, 1992). It has been demon-
strated to play a key role in several biological pro-
cesses including embryonic development, wound 
healing, tumor growth, and angiogenesis, mainly by 
providing a provisional matrix for supporting cellu-
lar migration and adherence (Laurent & Fraser, 1992; 
Knudson, 1996; Camenisch & McDonald, 2000; Lee 
& Spicer, 2000). Tethering of hyaluronan to the cell 
surface is mediated by HA-binding proteins, such as 
CD44 and RHAMM (receptor for HA-mediated mo-
tility) of which CD44 is considered as a major HA 
cell surface receptor (Day & Prestwich, 2002; Cichy 
& Pure, 2003; Ponta et al., 2003). Glycoprotein CD44 
is encoded by a single gene, but is expressed as mul-
tiple isoforms ranging in molecular mass from 80 to 
250 kDa. The heterogeneity of CD44 mainly results 
from alternative splicing of variable exons as well as 
differential posttranslational modifications including 
glycosylation and the attachment of glycosaminogly-
cans (GAGs) (Cichy & Pure, 2003; Ponta et al., 2003). 
Although CD44 is broadly expressed, including fi-
broblasts, keratinocytes, epithelial cells and leuko-
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cytes, in primary cells it usually does not exhibit a 
capacity to bind HA and requires activation to inter-
act with its ligand. Notably, generation of an active, 
HA-binding form of this receptor is responsible for 
most of CD44’s biological functions, such as myelo- 
and leukopoiesis, leukocyte extravasation and acti-
vation (Cichy & Pure, 2000; 2003; Ponta et al., 2003). 
There is an emerging evidence that HA as-
sociated with vessel wall contributes to targeting 
lymphocytes to inflammatory sites (DeGrendele et 
al., 1997; Mohamadzadeh et al., 1998; Siegelman et 
al., 1999; 2000). Recognition of vascular endothelium 
by immune cells and subsequent migration of these 
cells through the vessel wall is mediated by a mul-
tistep process that primarily involves: i/ selectins 
and their carbohydrate ligands, ii/ chemoatractants 
and their receptors, and iii/ integrins interacting 
with proteins of the immunoglobulin superfamily 
(Butcher & Picker, 1996). In addition, HA on endo-
thelial cells can initiate contact and mediate rolling 
of circulating cells bearing active form of CD44 (De-
Grendele et al., 1997; Siegelman et al., 1999; 2000). 
Interestingly, the CD44–HA interactions appear to 
be of particular significance in chronic inflammation 
and autoimmune diseases, including systemic lupus 
erythematosus and arthropathies where expression 
of CD44-dependent primary adhesion strongly cor-
relates with concurrent symptomatic disease (Est-
ess et al., 1998). The involvement of the CD44–HA 
complex in promoting chronic inflammatory condi-
tions is also supported by findings showing that ad-
ministration of anti-CD44 Ab that specifically blocks 
the CD44–HA interactions results in reduction of 
inflammatory symptoms such as T cell infiltrates 
and tissue edema in proteoglycan-induced arthritis, 
experimental allergic encephalomyelitis and insu-
lin-dependent diabetes mellitus (Mikecz et al., 1995; 
1999; Brocke et al., 1999; Weiss et al., 2000). In ad-
dition, CD44 and/or HA expressed on endothelial 
cells are well positioned to serve as an anchor for 
cancer cells disseminating through the blood stream. 
Indeed, CD44-mediated HA binding has been impli-
cated in the adhesion of a leukemic cell line to vas-
cular endothelial cells (Maiti et al., 1998).
Since the HA-mediated interactions between 
endothelium and leukocytes or disseminating tu-
mor cells play an important role in extravasation of 
circulating cells, there is a great need to determine 
the potential of endothelial cells to express HA. 
On the other hand, endothelial cell lines showing 
heterogeneity in their HA surface expression may 
provide a potential tool for identifying mechanisms 
underlying HA-mediated migration across vascular 
endothelium. Bearing this in mind, in this work we 
characterized immortalized human endothelial cells 
for HA deposition on the cell surface. Our results 
indicate that levels of endogenously produced HA 
differ between cells of different origin. Moreover, 
we demonstrate that CD44 does not provide a 
docking site for HA on the surface of the endothe-
lial cells examined.
MATERIALS AND METHODS
Reagents and antibodies. Biotinylated bo-
vine hyaluronic acid-binding protein (bHABP) was 
purchased from US Biological (Massachusetts, MA, 
USA). Phycoerythrin (PE)-conjugated streptavidin 
was obtained from BD Pharmingen (San Diego, CA, 
USA). The following anti-human CD44 mAbs were 
used: Hermes III, fluorescein (FITC)-labeled C-26 
(BD Pharmingen) and 5F12 that blocks HA binding 
(a generous gift of Dr. B. F. Haynes, Duke Univer-
sity Medical Center, Durham, NC, USA and Dr. E. 
Pure, Wistar Institute, Philadelphia, PA, USA). Puri-
fied hyaluronan from rooster comb was purchased 
from Sigma. Purified high molecular weight hy-
aluronan from human umbilical cord (HMW HA) 
was obtained from ICN Biomedicals (Costa Mesa, 
CA, USA). FITC-conjugated rooster comb HA (FITC-
HA) was prepared as described (de Belder & Wik, 
1975). FITC-conjugated anti-human CD3 antibody 
was purchased from BD Pharmingen. Anti-FITC Fab 
fragments of sheep IgG conjugated to horseradish 
peroxidase (HRP) were obtained from Roche Diag-
nostics (Mannheim, Germany). Hyaluronate lyase 
from Streptomyces hyalurolyticus was purchased from 
Sigma-Aldrich (Saint-Louis, MO, USA).
Cell culture. HLMEC — human lung microv-
ascular endothelial cells derived from immortalized 
HS888Lu cells from normal lung tissue of a patient 
with osteosarcoma metastatic to the lung; HPLNEC.
B3 — human peripheral lymph node endothelial 
cells taken from a cervical lymph node of a patient 
with Hodgkin’s lymphoma; HSKMEC.1 — human 
skin microvascular endothelial cells from normal 
skin; HIMEC.1 — human intestine microvascular en-
dothelial cells from normal intestine, and HAPEC.S1 
— human appendix endothelial cells isolated from 
a biopsy of a patient with appendicitis were estab-
lished as immortalized human endothelial cell lines 
as previously described (Bizouarne et al., 1993; Kie-
da et al., 2002). Human lung squamous carcinoma 
cell line (HTB58) and human breast adenocarcinoma 
(MDA-MB-231) were obtained from the American 
Type Culture Collection (Rockville, MD, USA). Cells 
were cultured in Dulbecco’s Modified Eagle Medi-
um (D-MEM) with high glucose (4.5 g/l d-glucose) 
supplemented with 50 μg/ml gentamycin and 2% 
heat-inactivated FBS (endothelial cells) or 10% FBS 
(HTB58, MDA-MB231) (all reagents from Invitrogen, 
UK). Cells were plated, allowed to grow to conflu-
ence and used for experiments.
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Flow cytometry. Cells were harvested using 5 
mM EDTA and stained as follows. The level of HA 
associated with the cell surface (endogenous HA) 
was determined after exposure of cells to bHABP 
followed by incubation with PE-conjugated strepta-
vidin. Exogenous (soluble) HA binding was assayed 
using saturating amounts of FITC-conjugated HA. 
Specificity of FITC-HA binding to the cell surface 
was determined by preincubation with an excess 
of unlabeled high molecular weight HA (HMW 
HA) for 20 min followed by labeling with FITC-
HA. CD44-mediated HA binding was assayed using 
HA-FITC. Negative reactivity was based on staining 
with HA-FITC in the presence of blocking anti-CD44 
mAb 5F12. To detect CD44, cells were stained with 
FITC-conjugated mouse anti-human CD44 antibody 
(C-26) or FITC-conjugated mouse anti-human CD3 
antibody as a negative control. All the results were 
obtained using FACScan and CellQuest software 
(BD Biosciences, San Jose, CA, USA).
Western blot analysis.  Cells were lysed in 
PBS containing 1% Nonidet P-40, 0.1% sodium de-
oxycholate, and protease inhibitors (1 mg/ml apro-
tinin, 100 μg/ml Pefabloc SC, 100 μg/ml leupeptin, 
and 100 μg/ml trypsin inhibitor). Cell lysates were 
normalized based on protein concentrations as de-
termined using the BCA kit (Sigma-Aldrich) and 
equal amounts of protein were subjected to immu-
noprecipitation with anti-CD44 mAb (Hermes III) 
conjugated to CNBr-activated Sepharose (Amer-
sham Pharmacia). Immune complexes were washed 
once with lysis buffer followed by three washes 
with PBS, and resolved on SDS/8% PAGE under 
nonreducing conditions. CD44 was visualized by 
enhanced chemiluminescence (ECL) (Pierce, Rock-
ford, IL, USA) after electrotransfer to a PVDF mem-
brane (Amersham Pharmacia Biotech) and incuba-
tion with FITC-conjugated mouse anti-CD44 anti-
bodies (C-26) and anti-FITC Fab fragments of sheep 
IgG conjugated to HRP.
RESULTS
Tissue-specific endothelial cell lines are heterog-
enous with respect to levels of HA associated with 
the cell surface
We employed immortalized human endothe-
lial cell lines originated from different tissues/organs 
as a model to determine whether HA is expressed 
on endothelial cells in a tissue-specific manner. The 
cells were isolated both from lymphatic organs (pe-
ripheral lymph nodes, appendix) and nonlymphatic 
sites (skin, lung and intestine). For each type of en-
dothelium different clones were obtained following 
immortalization and tested for endothelial features, 
such as the presence of von Willebrand factor, E- 
and P-selectin, CD34 and MAdCAM-1 (Kieda et al., 
2002). Clones that most-closely resembled tissue-
specific endothelium were chosen for these studies 
(Bielawska-Pohl et al., 2005). 
Surface levels of endogenously produced 
HA were assessed by flow cytometry using HA-
binding protein (bHABP). As shown in Fig. 1, all 
endothelial cells (EC) expressed this GAG on their 
surface. However, EC isolated from lung (HLMEC) 
expressed the highest levels of HA followed by in-
testine (HIMEC.1), lymph-node (HPLNEC.B3), skin 
(HSKMEC) and appendix-derived HAPEC.S1. No-
tably, the levels of HA associated with the surface 
of lung- (HLMEC) and intestine-derived endothelial 
cells (HIMEC.1) were higher compared with tumor 
cells originating from lung and breast epithelial cells 
(HTB58 and MDA-MB-231, respectively) (Fig. 1.), 
which had been previously shown to express signifi-
cant amounts of HA (Yu et al., 1997; Cichy & Pure, 
2000; 2004). These results suggest that, similar to 
other adhesion molecules (Butcher et al., 1999), the 
amount of HA retained on endothelium may de-
pend on its tissue origin. 
Exogenous HA is bound by EC
Endothelium lining blood vessels is charac-
terized by a thick surface coat known as glycoca-
lix that is mainly composed of glycoproteins and 
glycosaminoglycans (Baldwin & Thurston, 2001). 
Since all endothelial cell lines tested displayed 
significant levels of surface HA, we next exam-
ined whether all HA-binding sites are saturated 
with endogenous HA and whether these cells are 
still capable of binding additional exogenous HA. 
Cells were incubated with FITC-labeled exogenous 
HA in the presence or absence of an excess of un-
labeled high molecular weight HA (HMW HA) 
that was used as a competitive inhibitor. All lines 
tested except appendix-derived HAPEC.S1 exhib-
ited significant affinity for exogenous HA (Fig. 2), 
indicating the presence of HA-binding sites on 
their surface. 
There is accumulating evidence that surface 
HA binding can be attributed to the presence of 
CD44 in its active form (Cichy & Pure, 2000; 2004; 
Cichy et al., 2002). In order to determine wheth-
er CD44 mediates HA binding on the endotheli-
al cells, we used anti-CD44 antibody 5F12 which 
blocks the interaction between HA and CD44 
(Cichy & Pure, 2000). As demonstrated in Fig. 2, 
5F12 mAb did not significantly inhibit the bind-
ing of FITC-labeled HA to the surface of EC lines. 
In contrast, treatment with 5F12 mAb abrogated 
soluble HA binding to HTB58 and MDA-MB-231 
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epithelial tumor cells that express functional CD44 
(Cichy & Pure, 2000). The effect of anti-CD44 mAb 
on HA binding in tumor cells was similar to the ef-
fect of unlabeled high molecular weight HA, both 
of which diminished FITC-HA staining to baseline 
levels (Fig. 2). Taken together, these data indicate 
that CD44 does not participate in HA binding on 
the surface of tissue-specific endothelial cell lines.
EC do not express CD44
Since CD44 needs activation to bind HA, the 
CD44-independent HA binding on endothelial cells 
could result from expression of functionally inactive 
CD44 or a lack of this receptor on the cell surface 
under the experimental conditions. As shown in 
Fig. 3, flow cytometry analysis did not reveal CD44 
surface expression on any endothelial cell line ex-
amined. As expected, significant levels of CD44 
were detected in HTB58 and MDA-MB-231 tumor 
cells, consistent with previous reports (Cichy & 
Pure, 2000; Cichy et al., 2005). To determine wheth-
er endothelial cells are only deficient in surface 
CD44 or do not express CD44 at all, we performed 
CD44-specific immunoprecipitations followed by 
Western blot analysis. As demonstrated in Fig. 4, 
Figure 1. Basal levels of endog-
enous HA differ among endothe-
lial cell lines.
Flow cytometric analysis of en-
dogenous HA levels on endothe-
lial cells isolated from differ-
ent lymphatic (HPLNEC.B3 and 
HAPEC.S1) and nonlymphatic 
tissues (HIMEC.1, HLMEC and 
HSKMEC.1). The levels of HA as-
sociated with cell surface of non-
endothelial cancer cells, HTB58 
and MDA-MB-231, are shown as 
a control. Cells were labeled with 
biotinylated HA-binding protein 
(bHABP), followed by incubation 
with PE-conjugated streptavidin 
(solid lines) or PE-streptavidin 
only (dashed lines). (A) Mean 
fluorescence intensity from one 
representative experiment out of 
three independent experiments is 
shown. (B) Percentage of positive 
cells is shown as the mean ± S.D. 
from three independent experi-
ments.
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a predominant 90 kDa form and two additional 
species of CD44 with average molecular masses 
of 110 kDa and 180 kDa were immunoprecipitated 
from lysates of HTB58 cells and MDA-MB-231 tu-
mor cells. However, CD44 could not be detected 
in lysates of any of the tested endothelial cells, in-
dicating that CD44 is unlikely to contribute to the 
HA-related heterogeneity among EC.
DISCUSSION
Although extracellular organization and 
function of HA in a number of solid tissue micro-
Figure 2. Tissue-specific endothelial cells bind soluble 
exogenous HA.
Cells were labeled with FITC-conjugated HA and ana-
lyzed by flow cytometry (black bars). Nonspecific HA 
binding was determined by incubation with FITC-HA in 
the presence of an excess of high molecular weight unla-
beled HA (HMW HA) (white bars). Involvement of CD44 
in soluble HA binding was determined by pretreatment of 
cells with blocking anti-CD44 mAb 5F12 followed by in-
cubation with FITC-HA (grey bars). Percentage of positive 
cells is shown as the mean ±S.D. from three independent 
experiments. The difference between HA binding in the 
presence or absence of blocking anti-CD44 mAb 5F12 was 
statistically significant (Student’s t-test P < 0.05) only for 
HTB58 and MDA-MB-231 cells (*).
Figure 3. CD44 is not expressed on the sur-
face of endothelial cells.
Cell surface levels of CD44 were analyzed by 
flow cytometry after staining with FITC-conju-
gated anti-CD44 mAb (solid line) and a nega-
tive control FITC-conjugated anti-CD3 (dashed 
line). Results are expressed as mean fluores-
cence intensity of one representative experi-
ment out of three independent experiments.
Figure 4. Western blot analysis confirms lack of CD44 
expression in endothelial cells.
Indicated endothelial cells were lysed and half of the cell 
lysates were immunoprecipitated with Sepharose-conjugat-
ed anti-CD44 mAb Hermes III (lanes 1–7). To show specif-
icity, the remaining half of the cell lysates was subjected 
to immunoprecipitation with total mouse IgG (lanes 8–14). 
All samples were separated on SDS/PAGE under nonre-
ducing conditions, transferred to PVDF membrane, and 
incubated with mouse FITC-conjugated anti-human CD44 
mAb followed by HRP-conjugated anti-FITC Ab. Reactiv-
ity was then detected by ECL. Molecular mass markers in 
kDa are indicated.
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environments has been extensively examined, its 
deposition on the endothelium remains to be fully 
elucidated. HA has been reported to be associated 
with dermal microvasculature in skin of patients 
suffering from psoriasis (Tammi et al., 1994), indi-
cating the presence of this GAG on the endothe-
lium in vivo under conditions of chronic inflam-
mation. Moreover, endothelial cell lines and pri-
mary cultures of endothelial cells can be induced 
by proinflammatory mediators to express surface 
HA. Interestingly, the up-regulation of HA levels 
mediated by TNFα, IL1β and LPS appears to be 
restricted to small venular types of endothelium, 
consistent with a role of this type of endothelium 
in mediating leukocyte recruitment to inflamma-
tory sites (Mohamadzadeh et al., 1998). In addi-
tion, arterial, microvessel and large vein-derived 
endothelial cells have been described to differ in 
their ability to bind exogenous HA (Lokeshwar & 
Selzer, 2000). Taken together, these data support 
the notion that endothelial cells of different vas-
cular origins show heterogeneity in HA-mediated 
functions.
The studies presented here suggest that the 
amount of HA anchored to the endothelial cells 
may also be dependent on the tissue of origin of 
these cells. This is important in view of the fact 
that endothelium-specific addressins, includ-
ing MAdCAM-1, GlyCAM-1 and CD34 signifi-
cantly contribute to region/organ specific homing 
of immune cells (Butcher et al., 1999). Therefore, 
the differential levels of HA on EC derived from 
various tissues suggest that HA-mediated bind-
ing of circulating cells to endothelium may occur 
in a tissue-specific manner. However, we can not 
exclude the possibility that cell immortalization 
and/or tissue culture conditions also contribute to 
the observed heterogeneity among the endothelial 
cells studied. 
The overall lower levels of HA retained on 
endothelial cells isolated from lymphatic tissues 
(particularly from appendix), compared to EC de-
rived from nonlymphatic sites such as lung and in-
testine suggest that endothelial HA is more likely to 
support cell trafficking to extralymphatic sites. These 
results are consistent with the findings that T cell 
CD44-mediated interactions do not contribute to T 
cell recruitment to lymphoid tissues in the physio-
logical state but are rather involved in the trafficking 
of activated lymphocytes to the sites of inflamma-
tion or injury (Camp et al., 1993). 
The EC heterogeneity with respect to sur-
face HA levels could result from differences in the 
synthesis of this GAG, availability of functional 
HA-binding molecules on the cell surface, or a 
combination thereof. Since the different EC exam-
ined were capable of binding exogenous HA, the 
HA-binding sites were not saturated in these cells, 
potentially allowing binding of higher amounts of 
endogenously produced HA. Therefore differential 
HA expression in tissue-specific EC could be at 
least partially responsible for the observed differ-
ences in HA surface levels among these cells. On 
the other hand, appendix-derived HAPEC.S1 endo-
thelial cells that were found to contain the lowest 
amount of HA on the cell surface also displayed 
the lowest ability to bind soluble HA, indicating 
that HAPEC.S1 cells are deficient in HA-binding 
receptors. Taken together these results demonstrate 
that HA deposition on EC is dependent on both, 
HA synthesis and the availability of HA binding 
membrane molecules. 
In order to characterize the HA-binding 
sites on tissue-specific endothelial cells, we fo-
cused on CD44, which is well known to mediate 
immobilization of HA on a variety of cells (Knud-
son et al., 1996; Cichy & Pure, 2003). In addition, 
several reports have demonstrated CD44 expres-
sion on EC, including proliferating HUVEC and 
bovine aortic EC (Griffioen et al., 1997). However, 
our findings clearly indicate that CD44 is unlikely 
to serve as an anchor for HA on EC. Even though 
CD44 is considered a principal receptor for HA, 
other molecules may be involved in HA binding 
on endothelial cells since this GAG is well-known 
to interact with a large number of proteins col-
lectively known as hyaladherins. These include 
RHAMM and several components of the cellu-
lar matrix such as aggrecan and versican (Day 
& Prestwich, 2002). In addition, HA synthetases 
that are localized on the cytoplasmic surface of 
the cell membrane could potentially contribute to 
the retention of HA on cell surfaces (Camenisch 
& McDonald, 2000). Notably, in agreement with 
our findings, RHAMM but not CD44 has been 
implicated in mediating soluble HA binding on 
arterial, microvessel and vein-derived human EC 
(Lokeshwar & Selzer, 2000). Taken together these 
data indicate that, in contrast to other cells such 
as chondrocytes and epithelium that interact with 
HA in a CD44-dependent manner (Yu et al., 1997; 
Cichy & Pure, 2000; Knudson et al., 2002), endo-
thelial cells appear less likely to utilize this recep-
tor for HA binding and concomitantly assembly 
of the pericellular matrix based on a hyaluronan 
scaffold. Another indirect evidence supports struc-
tural differences in the HA-based matrix associ-
ated with EC compared to the HA-based matrix 
associated with epithelial tumor cell lines. This 
evidence is related to various effects of the HA-
degrading enzyme — a hyaluronidase on the dis-
ruption of the HA–cell interactions in these cells. 
Whereas pretreatment of HTB58 or MDA-MB-231 
tumor cells with hyaluronidase resulted in block-
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ing of bPG staining, hyaluronidase was not effec-
tive in removing surface HA from endothelial cells 
(not shown). 
Since the levels and organization of HA on 
the EC surface may function as important determi-
nants of EC biology under physiologic and patho-
logic conditions, the characterized EC lines represent 
a convenient tool to study the rolling interactions 
between circulating blood-borne leukocytes or can-
cer cells with tissue-specific endothelium. 
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